A neoantigen pioneer says its tech is working great. So what wrecked the share price?
Gritstone Oncology was one of the original neoantigen upstarts, raising cash and planning to disrupt the immuno-oncology field with a bold new approach to fighting cancer with a new brand of vaccines.
On Monday, the crew in charge ran out a full display of what they’ve been seeing in a Phase I study. And everything seems to be working perfectly with one big exception: It didn’t significantly shrink tumors, let alone eradicate them.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.